Company
Shanghai Henlius Biotech, Inc.
Headquarters: Shanghai, China
Employees: 2,234
CEO: Mr. Wenjie Zhang
Market Cap
HK$10.49 Billion
HKD as of Jan. 1, 2025
US$1.35 Billion
Shanghai Henlius Biotech, Inc. Categories
China Healthcare BiotechnologyChina Healthcare China Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases worldwide. The company offers HLX01, a rituximab injection for treating non- hodgkin lymphoma and chronic lymphocytic leukemia; Hanquyou, a trastuzumab injection for breast and metastatic gastric cancer; and Han Dayuan, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, and psopiasis and uveitis. It is developing HLX01 for the treatment of rheumatoid arthritis; HLX04 for colorectal and non-squamous non-small cell lung cancer; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX10 for solid tumors and hepatitis B virus; HLX10+Chemotherapy for metastatic esophageal squamous-cell carcinomas, squamous non-small cell lung cancer, small cell lung cancer, neo-/adjuvant treatment of gastric cancer, and cervical cancer; and HLX10+HLX04 for hepatocellular carcinoma, non-squamous, non-small cell lung cancer, and metastatic colorectal cancer. The company is also developing HLX10+HLX07 for squamous cell carcinoma of the head and neck; HLX07, HLX06, HLX56, and HLX20 for solid tumors; HLX05, a cetuximab injection for squamous cell carcinoma of the head and neck and metastatic colorectal cancer; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer; HLX22 for breast and metastatic gastric cancer; HLX55 for metastatic or recurrent solid tumors; HLX11 for breast cancer; HLX14 for osteoporosis; HLX13 for unresectable or metastatic melanoma, adjuvant treatment of melanoma, advanced renal cell carcinoma, and metastatic colorectal cancer; HLX15 for multiple myeloma; HLX26 for solid tumor and lymphoma; and HLX70 and HLX71 for COVID-19. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | HK$5.99 B |
| EBITDA | HK$1.07 B |
| Gross Profit TTM | HK$4.39 B |
| Profit Margin | 12.27% |
| Operating Margin | 16.32% |
| Quarterly Revenue Growth | 9.80% |
Stocks & Indices
Shanghai Henlius Biotech, Inc. has the following listings and related stock indices.
Stock: HKEX: 2696 wb_incandescent